TNFRSF9 and Granuloma: Nevertheless, trials are underway to examine the effects of combined coinhibitory receptor blockade and costimulatory receptor agonists, such as 4-1BB and OX40.42,43 These combinatorial therapies may serve to increase the chance of developing granulomas in TDLNs, as they are intended to synergistically boost the activation of T cells.